 |
|
|
|
 |
|
|
| Article 1 to 10 out of 18 concerning The Dow Chemical Company
|
-
Agilent Technologies Expands Therapeutic Nucleic Acids Manufacturing Capacity
(05/09/2008)
Dow Nucleic Acids Medicines Business Assets Acquired
Agilent Technologies Inc. announced the expansion of its nucleic acid active pharmaceutical ingredient (API) manufacturing facility in Boulder, Colo. Agilent's Nucleic Acids Solutions Division is adding large-scale nucleic acid synthesis, ...
-
Dow AgroSciences and Sangamo BioSciences Announce the Achievement of Multiple Milestones in Plant Agriculture Collaboration
(11/20/2006)
Dow AgroSciences LLC and Sangamo BioSciences, Inc. announced the successful completion of multiple research milestones as part of their Research and Commercial License Agreement initiated October 2005. The three-year agreement provides Dow ...
-
Dow Chemical's business unit Dowpharma(TM) will manufacture Alnylam's RNAi therapeutics
(07/04/2006)
Alnylam Pharmaceuticals, Inc. and Dowpharma(SM), a business unit of The Dow Chemical Company, announced an agreement for the manufacture and supply of candidate RNAi therapeutics for Alnylam's lead development programs in age-related macular ...
-
Aquapharm Bio-Discovery Ltd Enters a Collaboration Deal with DowpharmaSM Contract Manufacturing Services
(06/20/2006)
Aquapharm Bio-Discovery Ltd. (Aquapharm), a UK marine biotechnology company developing, amongst other things, nutraceutical and anti-infective drug candidates from marine natural products, has entered a collaboration with DowpharmaSM contract ...
-
VGX Pharmaceuticals and Dowpharma Sign Research and Development Agreement for VGX's Lead Cancer Compound
(03/02/2006)
VGX Pharmaceuticals and DowpharmaSM contract manufacturing services, a business unit of The Dow Chemical Company, announced they have signed a Research and Development Agreement to advance the development of VGX-100, VGX's novel cancer compound in ...
-
Dow AgroSciences, Sangamo BioSciences Announce Research and Commercial License Agreement in Plant Agriculture
(10/07/2005)
Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, and Sangamo BioSciences, Inc. announced the signing of a Research and Commercial License Agreement. The agreement provides Dow AgroSciences with access to Sangamo's ...
-
Alnylam Announces Manufacturing Agreement with Dowpharma(TM) for RNAi Therapeutics
(09/28/2005)
Alnylam Pharmaceuticals, Inc. and Dowpharma(SM), a business unit of The Dow Chemical Company, announced an agreement for the manufacture and supply of candidate RNAi therapeutics for Alnylam's lead development programs in age-related macular ...
-
Dow Chemical Subsidiary Granted U.S. Patent on Transgenic Bt in Plants
(09/14/2005)
Mycogen Plant Seeds, Inc., an affiliate of Dow AgroSciences LLC, has been granted U.S. patent rights to Transgenic Bt in Plants, according to an announcement issued by the U.S. Patent Office, September 13, 2005. Both Mycogen and Dow AgroSciences are ...
-
Dow and Cytogen Agree to Develop PSMA Antibody for Treatment of Cancer
(05/12/2005)
Cytogen Corporation and DowpharmaSM contract manufacturing services, a business unit of The Dow Chemical Company, announced a collaboration to create a targeted oncology product designed to treat prostate and other cancers. Under the agreement, ...
-
Alnylam Announces Manufacturing Agreement with DowpharmaSM for RNAi Therapeutics
(04/04/2005)
Alnylam Pharmaceuticals, Inc. and DowpharmaSM, a business unit of The Dow Chemical Company announced an agreement for the manufacture and supply of candidate RNAi therapeutics for Alnylam's lead development programs in age-related macular ...
|
|
|
|
|
Top
